GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Gross Profit

BCAL Diagnostics (ASX:BDX) Gross Profit : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Gross Profit?

BCAL Diagnostics's gross profit for the six months ended in Dec. 2023 was A$0.00 Mil. BCAL Diagnostics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BCAL Diagnostics's gross profit for the six months ended in Dec. 2023 was A$0.00 Mil. BCAL Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, BCAL Diagnostics's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

BCAL Diagnostics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


BCAL Diagnostics Gross Profit Historical Data

The historical data trend for BCAL Diagnostics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Gross Profit Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Gross Profit
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial - - - - -

Competitive Comparison of BCAL Diagnostics's Gross Profit

For the Diagnostics & Research subindustry, BCAL Diagnostics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Gross Profit distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Gross Profit falls into.



BCAL Diagnostics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BCAL Diagnostics's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

BCAL Diagnostics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

BCAL Diagnostics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BCAL Diagnostics  (ASX:BDX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BCAL Diagnostics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


BCAL Diagnostics Gross Profit Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.